Artificial intelligence to judge egg and embryo quality in infertility care
Tests computer analysis of eggs and embryos in people having fertility treatment.
Key facts
- Who runs it
- Charles University, Czech Republic
- Where
- Czechia4 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Aftificial Inteligence in Assisted Reproductive Techniques to Assess Oocyte Quality and Embryo Ploidy
- Status
- Recruiting
- People taking part
- 1,000 people, planned
- Started
- 5 Jan 2024
- Expected to end
- 31 Mar 2028
- Type of study
- Observational
- Treatments tested
- arteficial inteligence evaluation of oocyte and embryo development
- Record updated
- 22 January 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people having fertility treatment with ICSI (sperm injected directly into the egg). Their embryos also have genetic testing and time-lapse recording.
- Age
- 18 Years to 49 Years
- Sex
- All
- Disease stage
- Infertility, including female, male and unexplained infertility.
- Earlier treatment
- People must be having Intracytoplasmatic Sperm Injection (ICSI), Preimplantation genetic testing and time-lapse recording of the embryos.
Main reasons for not taking part
- Gynecological diseases (diseases of the female reproductive organs)
- Genetic diseases in either parent
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Intracytoplasmatic Sperm Injection
- Preimplantation genetic testing
- Time lapse embryo record
- Singned informed consent
Who cannot take part
- Gynecological diseases
- Genetical diseases of parents
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 49 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The assisted reproduction success rate is affected by several factors including the age of the women, oocyte quality and maturation state, as well as sperm quality. Imaging of the meiotic spindle may be crucial for determining the oocyte maturation. Artificial intelligence (AI) will be applied to establish the complex oocyte quality, embryo ploidy and pregnancy success probability from the sequence of data, starting with the recording of the meiotic spindle in polarized light, through paternal factors up to the time lapse recording of early embryo development. This strategy should reduce the cost of fertility treatment thanks to increased efficiency in choosing the most promising candidates and reducing the need for costly laboratory analyses.
Treatments tested
- arteficial inteligence evaluation of oocyte and embryo development
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Scanning the Meiotic Spindle in Assisted Reproductive Techniques to Assess Oocyte Quality and Embryo Ploidy Evaluated by Artificial Intelligence (SMARTAI Study)
- Plain-language title
- Artificial intelligence to judge egg and embryo quality in infertility careGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Fit questions
- Built from NCT06539104, who can take part
- Record updated
- 22 January 2025